Loading
A phase 2 trial of Plitidepsin in Multiple myeloma, run by PharmaMar, completed.
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT00229203 by PharmaMar, with 51 participants recorded, started 2005-02 and reaching its primary completion in 2008-08. Interventions recorded: Plitidepsin. Conditions recorded: Multiple Myeloma.
Linked to the drug Plitidepsin because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
51 enrolled.
range 1.4 to 2.6; Figures from the ClinicalTrials.gov results section (first posted 2009-12-14), not from a publication · range 3.1 to 7.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Plitidepsin | 21 | 2.3 months | - | - | link |
| Plitidepsin + Dexamethasone | 8 | 3.8 months |
Shares Plitidepsin, PharmaMar, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Plitidepsin and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.